Published in Ann Oncol on June 06, 2014
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology (2015) 1.06
Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. J Crohns Colitis (2016) 0.84
Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora? Semin Immunopathol (2017) 0.82
Stereotactic body radiotherapy for the pancreas: a critical review for the medical oncologist. J Gastrointest Oncol (2016) 0.80
Immune checkpoint therapy for pancreatic cancer. World J Gastroenterol (2016) 0.79
T cell exhaustion: from pathophysiological basics to tumor immunotherapy. Cell Commun Signal (2017) 0.78
Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events. Oncologist (2016) 0.78
Tremelimumab: research and clinical development. Onco Targets Ther (2016) 0.78
Viro-immune therapy: A new strategy for treatment of pancreatic cancer. World J Gastroenterol (2016) 0.77
Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. Sci Rep (2016) 0.75
Pancreatic cancer: Update on immunotherapies and algenpantucel-L. Hum Vaccin Immunother (2016) 0.75
Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma. World J Gastroenterol (2016) 0.75
Immunotherapy for patients with advanced pancreatic carcinoma: A promising treatment. Oncotarget (2016) 0.75
Immunotherapy in pancreatic cancer: Unleash its potential through novel combinations. World J Clin Oncol (2017) 0.75
Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer. Oncoimmunology (2017) 0.75
CTLA-4/CD80 pathway regulates T cell infiltration into pancreatic cancer. Cancer Immunol Immunother (2017) 0.75